At today's price, AbbVie's stock is pricing in roughly 10.7% annual free-cash-flow growth for the next ten years, at a 9% discount rate. Over the past five years, the company's actual free cash flow shrank 5.1% a year on average.
At its current price, ABBV implies ~10.7% annual free-cash-flow growth for the next 10 years, discounted at 9%.
AbbVie's actual free cash flow shrank 5.1% a year on average over the past five years.
Required growth vs. historical growth
Required growth from the reverse DCF below. Historical CAGRs calculated from 10-K FY2021–FY2025 (revenue $56.20B → $61.16B; FCF $21.99B → $17.82B).
Sensitivity: what if the discount rate moves?
| WACC | Required annual growth |
|---|---|
| 8% | 8.27% |
| 9% (base case) | 10.67% |
| 10% | 12.87% |
| 12% | 16.87% |
Even at the most conservative discount rate tested (8%), the market still requires at least 8% annual FCF growth — well above anything AbbVie has delivered on this measure over the past five years.
What would move this number
- Using a 3-year average FCF ($19.24B) instead of the trailing-twelve-month figure ($18.21B) lowers the required growth rate slightly, from 10.67% to 9.94% at a 9% discount rate — the conclusion doesn't change.
- Updating net debt to reflect the Aliada Therapeutics acquisition (completed September 2026, funded partly with new debt) would likely push the required growth rate higher than shown here — that acquisition's financing isn't yet reflected in this calculation.
- Lowering the terminal growth rate from 2.5% to 2.0% raises the required growth rate by roughly 0.2–0.3 percentage points.
Show your work
Five inputs, sources, model assumptions, and the calculation
- Share price$264.34 — stockanalysis.com, Sept. 25, 2026 close
- Diluted shares outstanding1.771B — 10-Q, Q2 FY2026 (quarter ended June 30, 2026), weighted-average diluted shares
- Market cap$468.1B — price × diluted shares
- Trailing-twelve-month FCF$18.21B — FY2025 operating cash flow $19.03B minus H1 2025's $6.79B, plus H1 2026's $7.27B, giving TTM operating cash flow of $19.51B, less TTM capex of $1.30B. Source: 10-K FY2025, p.55; 10-Q Q2 FY2026 and Q2 FY2025
- Net debt$64.25B — total debt $70.82B (short-term borrowings $0 + current portion of long-term debt $8.34B + long-term debt $62.48B) minus cash $6.57B, as of June 30, 2026. Source: 10-Q Q2 FY2026
- Discount rate (WACC)9% base case (8% / 10% / 12% tested); large stable pharmaceutical classification
FCF normalization check: the trailing-twelve-month figure of $18.21B is 5.3% below the 2023–2025 three-year average of $19.24B, well inside our ±40% threshold, so no adjustment was needed — the TTM figure was used as-is.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter. We solve by bisection for the value of g that makes the present value of those cash flows equal today's enterprise value.
| Component | Value |
|---|---|
| Market cap | $468.1B |
| Net debt | $64.25B |
| Target enterprise value | ~$532B |
EV = Σ(t=1..10) FCF₀×(1+g)ᵗ/(1+WACC)ᵗ + [FCF₀×(1+g)¹⁰×1.025/(WACC−0.025)]/(1+WACC)¹⁰, solved for g by bisection.
The fine print
- Change the discount rate, the projection window, the terminal growth rate, or how FCF is normalized, and the answer moves.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Whether 10.7% annual FCF growth is realistic depends on whether Skyrizi and Rinvoq keep growing, whether IRA price controls bite harder, and whether R&D and acquisition spending keeps weighing on cash flow — not on the math itself.
- Any investment decision, and its outcome, is your own responsibility.
How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.
Frequently asked questions
What growth rate does ABBV's stock price assume?
At its current price, AbbVie is pricing in roughly 10.7% annual free-cash-flow growth for the next ten years, discounted at a 9% rate.
How does that compare to AbbVie's actual growth?
AbbVie's free cash flow actually shrank at a 5.1% annual rate over the past five years, while revenue grew just 2.1% a year — both well below the roughly 10.7% annual free-cash-flow growth the current price requires.
What share price was used for this analysis?
This analysis used $264.34, AbbVie's closing price on Sept. 25, 2026.